摘要
高危人乳头瘤病毒16型的感染与宫颈癌的发病密切相关。HPV16E6和E7蛋白在大多数HPV16相关宫颈癌及其癌前病变中持续表达,因此E6和E7蛋白可作为制备HPV16相关肿瘤及其癌前病变治疗性疫苗的靶抗原〔2〕。采用套式PCR方法,从宫颈癌患者组织中扩增出E6、E7基因并成功构建了包含E6、E7的表达质粒PET-E6、PET-E7。SDS聚丙烯酰胺凝胶电泳和Western-blotting分析结果表明,外源基因E6,E7在T7启动子控制下可获得稳定表达。
Humanpapillomaviruus （HPV） type 16 （HPV16） infection in human is associated with most cervical cancers , and expression of the early oncogenic proteins E6 and E7 is required to maintain the transformed state of the tumor cell. Therefore,E6 and E7 are appropriate tumor-specific antigen and target for vaccine-based treatment of HPV-16-assoniated malignancies. Using Nested Polymerase Chain Reaction （PCR） , amplify HPVE6 and E7 gene, construct expressing plasraids PET-E6 and PET-E7 which containing the early gene E6 and E7. SDS-PAGE and Western-blot result showed that the cloned gene were expressed under the control of T7 promoter in E. coil DE3.
出处
《微生物学免疫学进展》
2007年第2期7-11,共5页
Progress In Microbiology and Immunology
